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There is some dissatisfaction with the term “nonalcoholic fatty liver disease (NAFLD),” which overemphasizes alcohol 
and underemphasizes the importance of metabolic risk factors in this disease. Recently, a consensus recommended 
“metabolic (dysfunction)-associated fatty liver disease (MAFLD)” as a more appropriate term to describe fatty liver 
diseases (FLD) associated with metabolic dysfunction. During the definition change from NAFLD to MAFLD, subjects with 
FLD and metabolic abnormalities, together with other etiologies of liver diseases such as alcohol, virus, or medication 
who have been excluded from the NAFLD criteria, were added to the MAFLD criteria, while subjects with FLD but without 
metabolic abnormality, who have been included in the NAFLD criteria, were excluded from the MAFLD criteria. This 
means that there is an emphasis on the metabolic dysfunction in MAFLD which may underestimate the prognostic value 
of hepatic steatosis itself, whereas the MAFLD criteria might better identify subjects who are at a higher risk of hepatic 
or cardiovascular outcomes. However, non-metabolic risk NAFLD subjects who are excluded from the MAFLD criteria 
are missed from the diagnosis, and their potential risk can be the cause of future diseases. Although huge controversies 
remain, this review focused on summarizing recent studies that compared the clinical and prognostic characteristics 
between subjects with NAFLD and MAFLD. (Clin Mol Hepatol 2021;27:257-269)
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INTRODUCTION
The term “nonalcoholic fatty liver disease (NAFLD)” was first in-
troduced by Schaffner and Thaler1 in 1986 to describe fatty liver 
disease (FLD) occurring in the absence of significant alcohol in-
take. This characterization overemphasizes the absence of alcohol 
use and underemphasizes the importance of metabolic risk factors 
that fuel the progression of liver disease in NAFLD.2 In addition, 
many criticisms have focused on the fact that NAFLD may trivial-
ize these diseases, reducing their consideration in the public 
health policy.
To date, it has become clear that NAFLD is a heterogeneous 
disorder with different metabolic and genetic factors involved in 
its pathogenesis contributing to its progression and prognosis.3,4 
The heterogeneous pathogenesis of NAFLD and inaccuracies in its 
definition necessitates a review of its nomenclature.5 In 2019, 
Eslam et al.2 provided suggestions on alternative terminologies 
that more accurately reflect the pathogenesis of this disease, 
which might help in patient stratification. Experts reached a con-
sensus that NAFLD does not reflect our current understanding of 
this disease, and metabolic (dysfunction)-associated fatty liver 
disease (MAFLD) might be a more appropriate overarching term.2
MAFLD represents a hepatic manifestation of systemic metabol-
ic dysfunction. MAFLD also warrants a “positive” diagnosis, ne-
gating a diagnosis based on the exclusion of other concomitant 
liver diseases. This novel nomenclature may be useful for clinical 
trials and research studies. In addition, the role of MAFLD in pa-
tients with concomitant liver disease has been recognized. How-
ever, since this change has not been fully accepted by major soci-
eties, future studies are required to confirm the feasibility of this 
novel terminology and to reach a consensus on the MAFLD crite-
ria. Moreover, non-metabolic risk (MR) NAFLD subjects who are 
excluded from MAFLD criteria are missed from the diagnosis, 
prompting caution in establishing follow-up strategy and assess-
ing the prognosis.
Our primary aim was not to review the recent studies on MAFLD 
without comparison to NAFLD, as the significant overlap between 
MAFLD and NAFLD might add only a few insights into the current 
literature. Instead, we focused on summarizing recent studies that 
compared the clinical and prognostic characteristics between sub-
jects with NAFLD and those with MAFLD, which might be helpful 
in deciding the use of optimal terminology in current clinical prac-
tice.
DIAGNOSTIC CRITERIA OF NAFLD AND MAFLD
NAFLD is defined by the 1) evidence of hepatic steatosis, either 
by imaging or histology, demonstrating the presence of steatosis 
in >5% of the hepatocytes, and the 2) lack of secondary causes 
of hepatic fat accumulation, such as significant alcohol consump-
tion (daily alcohol consumption ≥30 g for men and ≥20 g for 
women), long-term use of a steatogenic medication, or monogenic 
hereditary disorders (Table 1).6,7 In the majority of patients, 
NAFLD is commonly associated with metabolic comorbidities such 
as obesity, diabetes mellitus, and dyslipidemia.5
In contrast, the diagnosis of MAFLD is based on the histological 
(biopsy), imaging, or blood biomarker evidence of fat accumula-
tion in the liver, in addition to one of the following three criteria: 
overweight/obesity, presence of type 2 diabetes mellitus (T2DM), 
or evidence of metabolic dysregulation.8 The latter is defined by 
the presence of at least two metabolic risk abnormalities, as listed 
in Table 1.
Additionally, a panel of international experts have proposed 
that patients with cirrhosis who fulfill the diagnostic criteria for 
MAFLD should be considered as having MAFLD-related cirrhosis; 
therefore, the term “cryptogenic cirrhosis” should be avoided in 
this group.8 The diagnostic criteria for MAFLD-related cirrhosis in-
clude patients with cirrhosis in the absence of typical histological 
signs suggestive of steatohepatitis who fulfill at least one of the 
following: past or present evidence of metabolic risk factors that 
meet the criteria to diagnose MAFLD (Table 1), together with at 
least one of the following: 1) documentation of MAFLD on a pre-
vious liver biopsy, or 2) historical documentation of steatosis by 
hepatic imaging (Table 2). In particular, a history of alcohol intake 
should be considered, as patients may have dual disease etiology 
in the presence of alcohol use disorders.8
ADDED POPULATIONS ACCORDING TO MAFLD 
CRITERIA
A panel of international experts proposed a new definition for 
the diagnosis of MAFLD based on the presence of metabolic dys-
function and not the absence of other conditions.8 As a result, 
there is no reference to alcohol consumption or viral hepatitis in 
the MAFLD criteria, and this means that MAFLD can coexist with 
other liver diseases.2 Added population according to MAFLD crite-
ria included subjects who fulfilled the definition of MAFLD, but 
not the NAFLD criteria. The subjects in this specific population 
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showed FLD and metabolic abnormalities, together with other eti-
ologies of liver diseases such as alcohol, virus, or secondary 
causes including steatogenic medication or hereditary disorders 
(Fig. 1), who were excluded from the NAFLD criteria.
In a recent study by Zheng et al. focused on the PERSONS co-
hort;9 and of the 780 consecutively enrolled subjects with liver bi-
opsy, 663 (85%) fulfilled both the NAFLD and MAFLD criteria.10 
The difference in the number of subjects between the two groups 
(670 NAFLD vs. 773 MAFLD) was due to seven patients with FLD 
who were lean by body mass index (BMI) without satisfying the 
metabolic risk threshold (defined as non-MR NAFLD), and the in-
clusion of 110 patients with FLD and other etiologies of liver dis-
eases (66 with excess alcohol consumption, 40 with viral hepati-
tis, and four with autoimmune hepatitis). Notably, age, sex, 
comorbid diseases (i.e., diabetes mellitus and hypertension), vari-
ant distribution of the PNPLA3 gene, metabolic profile, and histol-
ogy, including liver steatosis and fibrosis, were not significantly 
different between the two groups. In a subgroup analysis of the 
MAFLD group, patients with MAFLD and significant alcohol con-
sumption presented with significantly higher gamma-glutamyl 
transferase levels and exhibited more severe liver steatosis com-
pared to the pure MAFLD (single etiology) group.
In another recent Taiwanese study by Huang et al.,11 175 pa-
tients with histology-verified liver steatosis and 10 with crypto-
genic cirrhosis were classified according to the diagnostic criteria 
of MAFLD and NAFLD. A total of 76 patients (41.1%) presented as 
both NAFLD and MAFLD, and nine patients (4.9%) had non-MR 
NAFLD, 81 patients (43.8%) had MAFLD without NAFLD, and the 
remaining 19 patients (10.3%) did not meet the criteria for either 
category. Although there was no significant difference in age or 
sex between the two groups, BMI was significantly higher in pa-
tients with MAFLD without NAFLD compared to the non-MR 
Table 1. Diagnostic criteria for NAFLD and MAFLD
NAFLD6,7 MAFLD8
For defining NAFLD, there must be
1)  evidence of hepatic steatosis, either by imaging or 
histology (steatosis in >5% of hepatocytes), and 
2)  lack of secondary causes of hepatic fat accumulation 
such as significant alcohol consumption (a daily 
alcohol consumption ≥30 g for men and ≥20 g for 
women), long-term use of a steatogenic medication, 
or monogenic hereditary disorders
In adults with hepatic steatosis (detected either by imaging techniques, blood 
biomarkers/scores, or liver histology), these three groups are classified as MAFLD
1)  Overweight/obesity (defined as BMI ≥25 kg/m2 in Caucasians or BMI ≥23 kg/m2 
in Asians)
2)  Lean/normal weight (defined as BMI <25 kg/m2 in Caucasians or BMI <23 kg/m2 
in Asians)
3)  Type 2 diabetes mellitus (according to widely accepted international criteria)
NAFLD, nonalcoholic fatty liver disease; MAFLD, metabolic-associated fatty liver disease; BMI, body mass index; HDL, high-density lipoprotein.
The presence of at least two of the following metabolic risk abnormalities:
•  Waist circumference ≥102/88 cm in Caucasian men and women (or ≥90/80 
cm in Asian men and women)
• Blood pressure ≥130/85 mmHg or specific drug treatment
•  Plasma triglycerides ≥150 mg/dL (≥1.70 mmol/L) or specific drug treatment
•  Plasma HDL-cholesterol <40 mg/dL (<1.0 mmol/L) for men and <50 mg/dL 
(<1.3 mmol/L) for women or specific drug treatment
•  Prediabetes (i.e., fasting glucose levels 100 to 125 mg/dL [5.6 to 6.9 mmol/L],  
or 2-hour post-load glucose levels 140 to 199 mg/dL [7.8 to 11.0 mmol] or 
HbA1c 5.7% to 6.4% [39 to 47 mmol/mol])
• Homeostasis model assessment of insulin resistance score ≥2.5
• Plasma high-sensitivity C-reactive protein level >2 mg/L
Table 2. Diagnostic criteria for MAFLD-related cirrhosis8
Patients with cirrhosis in the absence of typical histology who meet at least one of the following criteria:
Past or present evidence of metabolic risk factors that meet the criteria to diagnose MAFLD, as described in the small box in Table 1, with at 
least one of the following:
1) Documentation of MAFLD on a previous liver biopsy*
2) Historical documentation of steatosis by hepatic imaging*
MAFLD, metabolic-associated fatty liver disease.
*History of past alcohol intake should be considered as patients may have a dual disease etiology with alcohol use disorder. 
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NAFLD group (27.31 vs. 21.36 kg/m2; P<0.001). Among the 81 
patients with MAFLD without NAFLD, 35 (43.2%) presented with 
hepatitis B virus infection, 23 (28.4%) were taking culprit medica-
tions, 10 (12.3%) had hepatitis C virus infection, seven (8.6%) 
presented with autoimmune liver disease, five (6.2%) had chronic 
alcoholism, and one (1.2%) was positive for hepatitis E virus in-
fection. This group also included 19 patients (23.5%) with liver 
cirrhosis, 30 (37.0%) with hypertension, 26 (32.1%) with T2DM, 
and 16 (19.8%) with dyslipidemia, while none of these comorbidi-
ties were found in the non-MR NAFLD group. Moreover, patients 
with MAFLD, but without NAFLD, showed a significant increase in 
disease severity, as evaluated by both histology and laboratory 
findings, compared to those with non-MR NAFLD. Hepatitis B vi-
rus infection, hypertension, and T2DM were also independently 
associated with advanced fibrosis in patients with MAFLD.
In the most recent cross-sectional study of the National Health 
and Nutrition Examination Survey (NHANES) of the general popu-
lation of the USA, the prevalence of NAFLD and MAFLD were 
similar in the 1,710 subjects at 37.1% and 39.1%, respectively.12 
Only 13 subjects with NAFLD did not meet the MAFLD criteria 
(non-MR NAFLD), and 54 subjects with MAFLD did not meet the 
NAFLD criteria (MAFLD, but without NAFLD), mainly due to sig-
nificant alcohol consumption or the presence of viral hepatitis. 
None of the 13 subjects with non-MR NAFLD presented with ad-
vanced liver fibrosis; however, those with MAFLD, but without 
NAFLD, showed similar advanced fibrosis to the overall estimate. 
The prevalence of advanced fibrosis among subjects with NAFLD 
and MAFLD was 7.5% and 7.4%, respectively. The authors sug-
gested that the recent change in diagnostic criteria did not affect 
the prevalence of the condition in the general USA population. 
The clinical significance of studies using the MAFLD criteria is 
summarized in Table 3.
MISSED POPULATIONS WHEN USING MAFLD 
CRITERIA
Missed population according to MAFLD criteria includes the 
subjects who fulfilled the definition of NAFLD, but not MAFLD 
(subjects with non-MR NAFLD). These subjects present with FLD, 
but without metabolic abnormalities or other etiologies of liver 
disease (Fig. 1), while meeting the NAFLD criteria. Although pa-
tients with non-MR NAFLD comprise a minority of these popula-
tions, many studies comparing the clinical characteristics and 
long-term outcomes of subjects with non-MR NAFLD to those 
without NAFLD or MAFLD and those with MAFLD are actively on-
going. Given the ambiguity in the definition of non-MR NAFLD, 
appropriate therapeutic strategies remain unclear.
A recent study using the NHANES III database, which is a peri-
odic survey conducted by the Centers for Disease Control and Pre-
vention in the USA, focused on the comparison of subjects with 
MAFLD and those with non-MR NAFLD and severe steatosis.13 Al-
though the absolute sample size of the subjects with non-MR 
NAFLD was extremely small (n=46), comprising only around 1% 
of the subjects with MAFLD (n=4,087), and corresponding statisti-
cal errors cannot be completely removed, this study offered two 
Figure 1. Venn diagram highlighting the similarities and differences between NAFLD and MAFLD. NAFLD, nonalcoholic fatty liver disease; MAFLD, 
metabolic-associated fatty liver disease; FLD, fatty liver disease; MR, metabolic risk.
● Non MR-NAFLD
- Missed populations according to MAFLD criteria
-  Patients with fatty liver, but without matabolic 
abnormalities or other etiologies of liver disease
NAFLD
● MAFLD, but without NAFLD
- Added populations according to MAFLD criteria
-  Patients with fatty liver who have matabolic 
abnormalities and other etiologies including alcohol, 
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Table 3. Clinical significance of studies using MAFLD criteria
Study Number of patients Clinical significance
Zheng et al.10 Total/ NAFLD/MAFLD 780/670/773 1. Clinical characteristics including metabolic profile, 
comorbid disease, and histology were not different 
between NAFLD and MAFLD groups.
2. Patients with dual etiology (MAFLD and alcohol) had 
higher gamma-glutamyl transferase levels and exhibited 
more severe hepatic steatosis compared to pure MAFLD 
group (single etiology).
Both NAFLD and MAFLD 663
Non-MR NAFLD 7
MAFLD, but without NAFLD 110 (A/66, V/40, I/4)
Huang et al.11 Total/ NAFLD/MAFLD 166/85/157 1. MAFLD, but without NAFLD group exhibited a significant 
increase in disease severity, as evaluated by both histology 
and laboratory findings, compared to those with non-MR 
NAFLD.
2. MAFLD criteria included an additional 38.9% of patients 
with hepatic steatosis, and it can help identify those with a 
high degree of disease severity for early intervention better 
than the previous NAFLD criteria.
Both NAFLD and MAFLD 76
Non-MR NAFLD 9
MAFLD, but without NAFLD 81 (A/5, V/46, M/23, I/7)
Ciardullo and 
Perseghin12
Total/ NAFLD/MAFLD 728/674/715 1. None of the 13 subjects with non-MR NAFLD presented 
with advanced liver fibrosis. However, those with MAFLD, 
but without NAFLD, showed similar advanced fibrosis to 
the overall estimate. The prevalence of advanced fibrosis 
among subjects with NAFLD and MAFLD was 7.5% and 
7.4%, respectively.
2. The authors suggested that the recent change in 
diagnostic criteria did not affect the prevalence of the 
condition in the general USA population
Both NAFLD and MAFLD 661
Non-MR NAFLD 13
MAFLD, but without NAFLD 54 (NA)
Lee et al.16 Total/ NAFLD/MAFLD 3,628,540/2,680,217/3,573,644 1. A considerable proportion of middle-aged Korean adults 
have MAFLD, without satisfying the former definition of 
NAFLD. The change from NAFLD to MAFLD criteria may 
identify a greater number of individuals with metabolically 
complicated fatty liver and increased risk for CVD.
2. These studies might indicate that patients with non-MR 
NAFLD should be closely monitored, as they experience an 
increased risk for poor outcomes.
Both NAFLD and MAFLD 2,625,321
Non-MR NAFLD 54,896
MAFLD, but without NAFLD 948,323 (NA)
Yamamura et 
al.18
Total/ NAFLD/MAFLD 726/541/609 1. The MAFLD definition better identifies the group with 
fatty liver and significant fibrosis evaluated by non-invasive 
tests. Moreover, in patients with MAFLD, even mild alcohol 
consumption was associated with worsening of hepatic 
fibrosis measures.
2. It might be suggested that subjects with non-MR 
NAFLD might have no urgent diagnostic and therapeutic 
intervention needs due to a potentially favorable disease 
course.
Both NAFLD and MAFLD 424
Non-MR NAFLD 117
MAFLD, but without NAFLD 185 (NA)
Lin et al.22 Total/ NAFLD/MAFLD 13,083/4,347/4,087 1. MAFLD were significantly older and had higher BMI and 
higher proportions of metabolic comorbidities (T2DM, 
hypertension) compared to subjects with NAFLD.
2. Subjects with MAFLD and alcohol consumption were 
younger and had fewer metabolic disorders and a higher 
proportion of advanced fibrosis compared to those 
without.
Both NAFLD and MAFLD 3,727
Non-MR NAFLD 620
MAFLD, but without NAFLD 360 (NA)
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important clinical implications. First, although most metabolic pa-
rameters, including BMI, uric acid, lipid levels, HbA1c, and fasting 
sugar, were significantly lower in subjects with non-MR NAFLD 
and severe steatosis compared to those with MAFLD, their liver 
enzyme levels were statistically comparable (mean 24.00 IU/L in 
non-MR NAFLD and severe steatosis vs. 23.96 IU/L in MAFLD for 
alanine aminotransferase [ALT] level, P=0.990; mean 27.63 IU/L 
in non-MR NAFLD and severe steatosis vs. 25.35 IU/L in MAFLD 
for aspartate aminotransferase [AST] level, P=0.340). In addition, 
the degree of fibrotic burden, assessed by AST to platelet ratio in-
dex (APRI) and fibrosis-4 (FIB-4) index, was statistically similar 
between the two groups (mean 0.38 in non-MR NAFLD and se-
vere steatosis vs. 0.26 in MAFLD for APRI, P=0.275; mean 1.25 in 
non-MR NAFLD and severe steatosis vs. 1.06 in MAFLD for FIB-4, 
P=0.486). Therefore, the authors insisted that the degree of liver 
damage is similar between subjects with MAFLD and those with 
non-MR NAFLD and severe steatosis who cannot be classified as 
MAFLD. This means that, despite their relative rarity, subjects 
with non-MR NAFLD should not be ignored; rather, more atten-
tion is needed for accurate assessment and appropriate therapeu-
tic interventions in clinical practice. Second, this study highlighted 
that subjects with non-MR NAFLD and severe steatosis were sig-
nificantly younger than those with MALFD (mean 40 vs. 48 years). 
To date, the unfavorable influence of hepatic steatosis on long-
term outcomes, such as the increased risk of developing cardio-
vascular disease (CVD) events and T2DM, have been well report-
ed.14,15 In addition, hepatic steatosis can develop as the first 
manifestation of overt metabolic dysfunction, and increased age 
is a significant predictor of metabolic syndrome. These facts indi-
cate that regular monitoring is needed for younger subjects with 
non-MR NAFLD and severe steatosis, who currently do not show 
metabolic dysfunction but may develop various metabolic pheno-
types, including MAFLD. In another recent study conducted in 
South Korea, the proportion of subjects with non-MR NAFLD was 
only 0.6%.16 Although the comparison between subjects with 
non-MR NAFLD and those with MAFLD was not feasible, the ad-
justed risk of CVD in subjects with non-MR NAFLD was slightly 
increased with statistical significance (hazard ratio [HR], 1.09; 
95% confidence interval [CI], 1.03–1.15) compared to subjects 
without NAFLD or MAFLD. Among the surrogates of CVD, the risk 
of myocardial infarction specifically increased (HR, 1.14). These 
studies might indicate that patients with non-MR NAFLD should 
be closely monitored, as they experience an increased risk for 
poor outcomes.
In contrast, a recent Chinese study using the NHANES III data-
base showed that the proportion of subjects with non-MR NAFLD 
was higher (6.3%; n=793 of 12,571) in these populations, and 
that the subjects presented with favorable renal outcomes com-
pared to those with MAFLD (6.93% vs. 14.02% for albumin-to-
creatinine ratio; mean 83.49 vs. 74.06 mL/min/1.73m2; 6.43% vs. 
20.28% for stage 3–5 chronic kidney disease; all P<0.05).17 In 
another study from Japan, the proportion of non-MR NAFLD was 
15.3% and MAFLD without NAFLD was 24.2% among the sub-
jects with FLD.18 Group comparison showed significant elevations 
Study Number of patients Clinical significance
Wai-Sun Wong 
et al.23
Total/ NAFLD/MAFLD 277/261/263 1. The prevalence of NAFLD and MAFLD was 25.7% and 
25.9%, respectively, and the addition of the MAFLD criteria 
did not significantly change the prevalence of NAFLD.
2.  However, the incidence of MAFLD was 25% lower than 
that of NAFLD. This difference was predominantly observed 
in subjects with a BMI of <23 kg/m2. This data suggests 
that the new MAFLD criteria may exclude patients with a 
more benign clinical course.
Both NAFLD and MAFLD 247
Non-MR NAFLD 14
MAFLD, but without NAFLD 16 (A/3, V/13)
Niriella et al.24 Total/ NAFLD/MAFLD 1028/940/990 1. Although NAFLD and MAFLD had similar metabolic traits 
at baseline and similar outcomes after 7-years, the MAFLD 
but without NAFLD group seemed to have higher risk of 
adverse outcomes compared to the non-MR NAFLD group. 
Although the increase in the index population was small, 
redefining NAFLD as MAFLD seemed to improve clinical 
utility.
Both NAFLD and MAFLD 902
Non-MR NAFLD 38
MAFLD, but without NAFLD 88 (NA)
MAFLD, metabolic-associated fatty liver disease; NAFLD, nonalcoholic fatty liver disease; MR, metabolic risk; A, alcohol consumption; V, viral hepatitis; I, 
autoimmune hepatitis; M, medication; NA, not available; CVD, cardiovascular disease; BMI, body mass index; T2DM, type 2 diabetes mellitus.
Table 3. Continued
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in the fatty liver index, APRI, NAFLD fibrosis score, and liver stiff-
ness, assessed using transient elastography, in MAFLD without 
NAFLD compared to non-MR NAFLD (Table 4), which might indi-
cate that subjects with non-MR NAFLD might appear less severe 
than those with MAFLD, despite the comparable long-term impli-
cations of these diseases. These findings suggest that subjects 
with non-MR NAFLD might have no urgent diagnostic and thera-
peutic intervention needs, due to a potentially favorable disease 
course.
Although huge controversies still remain, the emphasis on met-
abolic dysfunction to define the subjects with MAFLD might un-
derestimate the prognostic value of hepatic steatosis itself; there-
fore, it seems that subjects with non-MR NAFLD, a new disease 
category, who might have an intermediate risk of metabolic dys-
function when comparing subjects with neither NAFLD nor 
MAFLD and those with MAFLD, require clinical attention. In addi-
tion, varying metabolic phenotypes should be compared between 
subjects without NALFD or MALFD, those with non-MR NAFLD, 
and those with MAFLD. If feasible, histopathological interpreta-
tion or comparisons are warranted to elucidate the characteristics 
of non-MR NAFLD. Recently, a Taiwanese study using only histo-
logical information11 showed that 42.8% of the patients with 
MAFLD (67 of 157) presented with advanced liver fibrosis, while 
none of the nine subjects with non-MR NAFLD did.
GENETICS
The pathogenesis of NAFLD is complex and likely shaped by the 
dynamic interactions between genetic susceptibility and environ-
mental factors. These factors interact with environmental, dietary, 
and metabolic risk factors, which contribute to the development 
of NAFLD and the risk of disease progression. Different genes en-
code proteins involved in the regulation of lipid metabolism in the 
liver. Over the past two decades, sequence variations in various 
genetic loci, including PNPLA3, TM6SF2, GCKR , MBOAT7, and 
HSD17B13, have been shown to increase NAFLD susceptibility.19 
These genes can be used in clinical risk stratification and person-
alized therapy. However, the role of these genetic variations in pa-
tients with MAFLD, which is a newly proposed disease category, 
have not been fully investigated, and further evaluation is needed.
A recent study by Liu et al.20 reported the genotype data from 
160,979 subjects in the UK Biobank, derived from a GWAS chip 
(Affymetrix UK BiLEVE and UK Biobank Axiom arrays). The impact 
of MAFLD, especially on hepatic events, was amplified by a high 
genetic risk score, of which genetic variations in PNPLA3 , 
TM6SF2, and MBOAT7 play principal roles. However, the ampli-
fied effects of high genetic risk scores for each of these genes 
were not found in subjects with lean MAFLD, which was defined 
as MAFLD with a BMI <25 kg/m2.
A retrospective case-control study evaluated the association of 
single nucleotide polymorphisms with the risk of MAFLD in a Sin-
gaporean Chinese population and their interactions with environ-
mental and medical risk factors.21 This study found that PNPLA3 
GG was more likely to be associated with MAFLD (43.4% CC vs. 
69.7% GG, P=0.017 and 44.8% CG vs. 69.7% GG, P=0.022), while 
variations in LYPLAL1, GCKR, FDFT1, COL13A1, PZP, and TM6SF2 
were not significantly associated with these patients.
The influence of genetic variation can be translated into more 
precise clinical management, which should be tailored to each in-
dividual patient with MAFLD.
COMPARISON BETWEEN NAFLD AND MAFLD: 
CROSS-SECTIONAL CONSIDERATIONS
Lin et al.22 recently reported real-world data comparing NAFLD 
and MAFLD (Table 5). They analyzed 13,083 subjects from the 
third NHANESs of the United States, and classified 4,087 (31.2%) 
subjects with MAFLD and 4,347 (33.2%) with NAFLD. When 
Table 4. Comparisons of the severity of hepatic steatosis and fibrosis between non-overlapping NAFLD and MAFLD groups
Surrogates Non-MR NAFLD (n=117) MAFLD, but without NAFLD (n=185) P-value
Fatty liver index 6 (3 to 11) 50 (32 to 71) <0.001
APRI 0.2 (0.2 to 0.3) 0.3 (0.2 to 0.4) <0.001
NAFLD fibrosis score −2.582 (−3.366 to −1.926) −1.689 (−2.770 to −0.829) <0.001
Liver stiffness (kPa) 5.2 (4.2 to 6.3) 7.6 (5.8 to 11.5) <0.001
Values are presented as median (interquartile range).
NAFLD, nonalcoholic fatty liver disease; MAFLD, metabolic-associated fatty liver disease; MR, metabolic risk; APRI, aspartate aminotransferase to platelet ratio 
index; FIB-4, fibrosis-4.
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these subjects were compared, they found that patients with 
MAFLD were significantly older and had higher BMI and higher 
proportions of metabolic comorbidities (T2DM, hypertension) 
compared to the subjects with NAFLD. Subjects with MAFLD and 
alcohol consumption were younger and had fewer metabolic dis-
orders and a higher proportion of advanced fibrosis compared to 
those without. This data suggest that the MAFLD criteria are 
practical and provide physicians with the opportunity to treat pa-
tients holistically, rather than focusing on individual organ sys-
tems.
Yamamura et al.18 also reported that MAFLD was better at iden-
tifying subjects with significant liver fibrosis than NAFLD in their 
study of 765 Japanese subjects with FLD. Liver stiffness using 
shear wave elastography was significantly higher in MAFLD than 
in NAFLD (7.7 vs. 6.8 kPa, P=0.001). Using decision-tree analysis, 
MAFLD, without NAFLD and alcohol consumption, was the initial 
classifier for significant liver fibrosis.
In contrast, Wai-Sun Wong et al.23 reported the impact of 
MAFLD criteria on the epidemiology of FLD by analyzing 922 
adults from the Hong Kong census database. The prevalence of 
NAFLD and MAFLD was 25.7% and 25.9%, respectively, and the 
addition of the MAFLD criteria did not significantly change the 
prevalence of NAFLD. However, the incidence of MAFLD (2.8/100 
person-years) was 25% lower than that of NAFLD (3.7/100 per-
son-years). This difference was predominantly observed in sub-
jects with a BMI of <23 kg/m2 (0.9 vs. 2.2/100 person-years). 
These data suggested that the new MAFLD criteria may exclude 
patients with a more benign clinical course.
COMPARISON OF NAFLD AND MAFLD: LONGI-
TUDINAL CONSIDERATIONS
Although the prognostic significance of MAFLD has been inves-
tigated in various clinical settings, few studies have investigated 
the prognostic value of MAFLD in comparison with NAFLD. A re-
cent community-based cohort study by Niriella et al.24 conducted 
in suburban Sri Lanka reported the findings for a study in which 
subjects were randomly selected in 2007 and then reassessed in 
2014 to evaluate the new-onset metabolic traits and CVD events. 
In this study, among the 2,985 subjects recruited in 2007, 940 
(31.5%) had NAFLD, 990 (33.1%) had MAFLD, and 362 (12.1%) 
were controls. MAFLD captured an additional 2.9% and lost 1.3% 
of all study subjects when compared to NAFLD, and at baseline, 
the anthropometric and metabolic traits were similar between the 
two groups. At the 7-year follow-up, the risk of new-onset meta-
bolic traits and fatal/non-fatal CVD events were similar in both 
groups, but significantly higher compared to the controls (Table 6). 
Those excluded by the NAFLD definition but captured by the 
MAFLD definition (MAFLD, but without NAFLD) showed higher 
baseline metabolic traits compared to those excluded by the 
MAFLD definition but captured by the NAFLD definition (non-MR 
NAFLD), and had a substantially higher risk of new-onset meta-
bolic traits and CVD events compared to the controls. Therefore, 
these authors concluded that redefining NAFLD as MAFLD 
seemed to improve clinical utility.
Another nationwide cohort study from South Korea conducted 
by Lee et al.16 evaluated the prevalence of FLD, including MALFD 











NAFLD vs.  
non-MR NAFLD
MAFLD vs.  
non-MR NAFLD
Age (years) 46.81±15.77 48.39±15.20 35.13±13.44 <0.001 <0.001 <0.001
Male (%) 2,014 (46.33) 2,036 (49.82) 249 (40.16) 0.001 0.004 <0.001
BMI (kg/m2) 29.49±6.69 30.68±6.25 21.67±2.08 <0.001 <0.001 <0.001
Diabetes (%) 1,092 (25.12) 1,171 (28.65) 0 (0) <0.001 <0.001 <0.001
Hypertension (%) 1,343 (30.89) 1,463 (35.80) 26 (4.19) <0.001 <0.001 <0.001
ALT (IU/L) 22.31±21.34 23.96±22.22 16.81±17.84 <0.001 <0.001 <0.001
NFS score −2.18±1.52 −2.05±1.51 −3.00±1.32 <0.001 <0.001 <0.001
FIB-4 score 1.01±0.84 1.06±1.35 0.87±1.05 0.033 0.002 <0.001
Values are presented as mean±standard deviation or number (%).
NAFLD, nonalcoholic fatty liver disease; MAFLD, metabolic-associated fatty liver disease; MR, metabolic risk; BMI, body mass index; ALT, alanine 
aminotransferase; NFS, NAFLD fibrosis score; FIB-4, fibrosis-4.
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and NAFLD, and the associated CVD risk using each of these defi-
nitions. From a nationwide health screening database, a total of 
9,584,399 subjects (48.5% male) aged 40–64 years between 
2009 and 2010 were included. These subjects were categorized 
by the presence of NAFLD and MAFLD, separately, and by the 
combination of the two definitions: neither-FLD, NAFLD-alone 
(non-MR NAFLD), MAFLD-alone (MAFLD, but without NALFD), or 
both-FLD. The prevalence of NAFLD and MAFLD were 28.0% and 
37.3%, respectively. The median follow-up period was 10.1 years. 
NAFLD and MAFLD were associated with a significantly higher 
risk for CVD events. When the neither-FLD group was the refer-
ence, multivariable-adjusted HRs (95% CI) for CVD events were 
1.09 (1.03–1.15) in the NAFLD-alone group, 1.43 (1.41–1.45) in 
the MAFLD-alone group, and 1.56 (1.54–1.58) in the both-FLD 
groups, indicating the highest risk of CVD in the MAFLD group 
(Table 7). Given this, the authors concluded that a considerable 
proportion of middle-aged Korean adults have MAFLD, without 
satisfying the former definition of NAFLD, and that the change 
from NAFLD to MAFLD criteria may identify a greater number of 
individuals with metabolically complicated fatty liver and in-
creased risk for CVD.










Adjusted RR  
(95% CI)
P-value
Adjusted RR  
(95% CI)
P-value
Incident general obesity 9/254 (3.5%) 51/215 (24.6%) 7.7 (3.8–15.4) <0.001 57/213 (26.8%) 8.3 (4.1–16.6) <0.001
Incident central obesity 39/246 (15.9%) 37/109 (33.9%) 2.6 (1.8–3.8) <0.001 44/101 (43.6%) 3.3 (2.3–4.7) <0.001
Incident diabetes 31/243 (12.8%) 203/503 (40.4%) 3.1 (2.2–4.4) <0.001 216/523 (41.3%) 3.2 (2.3–4.5) <0.001
Incident hypertension 36/218 (16.5%) 109/232 (33.7%) 2.1 (1.4–2.8) <0.001 111/326 (34.0%) 2.1 (1.5–2.9) <0.001
Incident 
hypertriglyceridemia
68/231 (29.4%) 145/361 (40.2%) 1.3 (1.1–1.7) 0.026 153/372 (41.1%) 1.4 (1.1–1.7) 0.010
Incident hypo HDL 
cholesterolemia
68/208 (32.7%) 246/461 (53.4%) 1.5 (1.2–1.7) <0.001 250/487 (51.3%) 1.5 (1.2–1.8) <0.001
CVD non-fatal and fatal 
events
4/253 (1.6%) 36/665 (5.4%) 3.7 (1.3–10.3) 0.013 43/692 (6.2%) 4.2 (1.5–11.5) 0.006
CVD, cardiovascular disease; NAFLD, nonalcoholic fatty liver disease; MAFLD, metabolic-associated fatty liver disease; RR, relative risk; CI, confidence interval; 
HDL, high-density lipoprotein.
*The number in the original 2007 cohort irrespective of the presence or absence of baseline condition. Individuals with existing condition at baseline were 
excluded in the calculation of risk ratios.
Table 7. Cardiovascular disease risk according to the presence and combination of NAFLD and/or MAFLD
Group Event Person-years Rate*
Hazard ratio (95% confidence interval)
Model 1 Model 2 Model 3
No NAFLD 108,283 63,604,662 170.2 1.00 (reference) 1.00 (reference) 1.00 (reference)
NAFLD 74,140 23,921,515 309.9 1.82 (1.80–1.84) 1.40 (1.38–1.41) 1.41 (1.40–1.43)
No MAFLD 81,235 55,715,210 145.8 1.00 (reference) 1.00 (reference) 1.00 (reference)
MAFLD 101,188 31,810,967 318.1 2.18 (2.16–2.20) 1.56 (1.54–1.57) 1.52 (1.51–1.54)
Neither FLD 79,987 55,203,158 144.9 1.00 (reference) 1.00 (reference) 1.00 (reference)
Non-MR NAFLD 1,248 512,052 243.7 1.68 (1.59–1.78) 1.20 (1.13–1.27) 1.09 (1.03–1.15)
MAFLD, but without NAFLD 28,296 8,401,504 336.8 2.33 (2.30–2.36) 1.55 (1.52–1.57) 1.43 (1.41–1.45)
Both FLD 72,892 23,409,463 311.4 2.15 (2.13–2.17) 1.57 (1.55–1.58) 1.56 (1.54–1.58)
Model 1 was unadjusted; model 2 was adjusted for age and sex; and model 3 was further adjusted for household income quartile, residential area, Charlson 
comorbidity index, tobacco use, exercise frequency, and estimated glomerular filtration rate.
NAFLD, nonalcoholic fatty liver disease; MAFLD, metabolic-associated fatty liver disease; MR, metabolic risk; FLD, fatty liver disease.
*Per 100,000 person-years.
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CLINICAL IMPLICATIONS OF THE TERMINOL-
OGY CHANGE
Patients who are well-informed and understand their condition 
can actively collaborate with their doctor to improve self-care and 
their quality of life, especially those with chronic disease.25 There 
is a growing awareness of the weaknesses inherent in the term 
“non-alcoholic,” which overemphasizes “alcohol.” The term “non-
alcoholic” leads to the question, “If my disease is not alcohol-re-
lated, then what is the real cause?”26 The traditional terminology 
of “NAFLD” not only confuses patients in terms of the real cause 
of their disease, but can also lead to adverse consequences in 
terms of doctor-patient communication.
Recently, the overestimation of the exclusion of alcohol has 
sparked some heated debate about the threshold for “significant” 
alcohol consumption for the diagnosis of NAFLD. Different defini-
tions of “significant” alcohol consumption are also present in the 
universal guidelines.6,7,27 For example, the European Association 
for the Study of the Liver guideline suggests that the diagnosis of 
NAFLD requires the exclusion of daily alcohol consumption ≥30 g 
for men and ≥20 g for women.7 Both the American Association 
for the Study of Liver Diseases and the Asian Pacific Association 
for the Study of the Liver guidelines define heavy or at-risk drink-
ing as more than 14 drinks per week for men or more than seven 
drinks per week for women.6,27 In addition, the potential (contra-
dictory) role of alcohol consumption in these “non-alcohol” dis-
eases has been repeatedly raised. A large study of 58,927 partici-
pants with NAFLD demonstrated that light or moderate alcohol 
consumption is associated with worsening of fibrosis when com-
pared to no consumption,28 while another prospective cohort 
study of 9,559 participants indicated that modest alcohol con-
sumption markedly, and perhaps synergistically, increases the risk 
of developing cirrhosis when combined with obesity.29 In addition, 
patients diagnosed with NAFLD may interpret the name “non-al-
coholic” as a license to continue drinking.26
Trivialization is considered a form of stigma as a minimizing ac-
tion in which the disease is perceived as easy to obtain or treat, 
and it might lead to adverse disease outcomes.30 This mainly aris-
es when disease perceptions or diagnoses are confusing. In fact, 
subjects with NAFLD experience trivialization of the disease. Sev-
eral studies have reported that more than 95% of subjects with 
suspected NAFLD are still unaware of having liver disease, and 
most subjects (>75%) do not feel that they are at risk of develop-
ing NAFLD.31-33 A recent report of a semi-structured interview 
with 136 subjects with NAFLD showed that the subjects tended 
to trivialize their condition.34 Most subjects (>80%) indicated that 
they were not concerned at all, while in comparison, >90% of the 
subjects indicated that they would be very concerned if they were 
told they had either hepatitis C or diabetes. Notably, 92% of the 
subjects expressed major dissatisfaction with the term “NAFLD,” 
mainly as it included the term “alcohol” in its name. While 72.8% 
of the subjects said they preferred the term “MAFLD,” 5.8% indi-
cated that they did not prefer this change. Moreover, a recent sur-
vey with 191 physicians presented that 96% of the subjects had a 
substantial lack of knowledge regarding the differences between 
NAFLD and NASH, even though they were aware of both.35 There-
fore, changing the name is expected to decrease trivialization and 
increase awareness of the disease, leading patients to recognize 
the importance and effectiveness of critical lifestyle changes nec-
essary to mitigate disease progression.
The term “non-alcoholic” underemphasizes the importance of 
metabolic dysfunction. A reorientation of the disease name to 
MAFLD, which includes the term “metabolic,” may lead to better 
patient-to-physician communication and improve decision sharing 
by reducing the patients’ confusion about the real cause of their 
disease. In addition, it is expected to help engage more health-
care systems and establish collaboration with other populations 
with increased metabolic risks (e.g., diabetes, renal disease, and 
CVD).36 Also, using the word “metabolic” in the context of the 
acronym hinges on the fact that MAFLD is potentially preventable 
and emphasizes the need for appropriate resource allocation and 
effective public health policy decisions. Changing the terminology 
has significant implications for the pharmaceutical industry, such 
as stimulating shared funding with other metabolic diseases and 
implementing effective system-wide interventions.
FUTURE DIRECTIONS
Part of the terminology change for MAFLD involves removing 
the term “non-alcoholic steatohepatitis” as a distinct subtype, 
and instead adopting a more fluid description based on grade and 
stage. MAFLD is viewed as a disease process in which simple ste-
atosis (MAFLD with no inflammation and fibrosis) merges into 
MAFLD with; for example, grade 1 inflammation and stage 2 fi-
brosis to MAFLD with grade 0 inflammation and stage 4 fibrosis.37 
Notably, previous studies of biopsy-proven NAFLD showed that 
the presence of NASH did not increase the risk of liver-specific 
morbidity or overall mortality. However, abandoning the term 
“steatohepatitis” could derail the ongoing clinical trials that were 
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designed in concert with the guidance around NASH drug devel-
opment.38 In this same context, some doubts have been raised as 
to whether now is the right time to change the name. It cannot be 
concluded that the terminology change will result in a new under-
standing of the disease. Therefore, some experts say it is not yet 
the time to impose another inappropriate term that needs to be 
corrected, as the understanding of the natural history, etiology, 
and management of NAFLD continues to be improved.38,39
NAFLD still contains a wide variety of disorders, and metabolic 
syndromes do form part of its spectrum (probably a major part) as 
a relatively sterile therapeutic armamentarium. Moreover, there 
are concerns that this may paradoxically result in misleading treat-
ments for the concomitant metabolic disorders. However, NAFLD 
is a dynamic disease characterized by several factors that can 
change over time. Therefore, multiple phenotypic measurements 
still need to be further analyzed as separate components, reflect-
ing the complex spectrum of this disease. Also, further clarifica-
tion and stratification of MAFLD are needed to guide decision-
making and prognostication from a clinical perspective. 
SUMMARY AND CONCLUSIONS
Two recent studies have suggested that the MAFLD criteria can 
identify patients with a higher degree of disease severity.11,16 In 
contrast, another study showed that the MAFLD criteria might 
overlook the clinical and prognostic significance of non-MR 
NAFLD.16 Notably, several recent studies have shown that the clin-
ical characteristics, including renal function and fibrosis markers, 
of subjects with non-MR NAFLD might be better than those of 
subjects with MAFLD.17 However, another study showed that sub-
jects with non-MR NAFLD had a higher risk of CVD compared to 
those with neither NAFLD nor MAFLD, indicating the need for 
careful assessment and monitoring of this population.16 In addi-
tion, more studies are required to better elucidate the potential 
risk that can be the cause of future disease in the “lean” NAFLD 
subjects without any metabolic dysregulation who are excluded 
from the MAFLD criteria.
The role of genetic variation among subjects with MAFLD has 
not been fully investigated. Although one study indicated that 
PNPLA3 GG was more likely to be associated with MAFLD,40 the 
influence of genetic variation should be investigated and tailored 
to each subject. The MAFLD criteria seem to better identify sub-
jects at higher risk of liver-related complications, as documented 
in a recent cross-sectional study. In addition, two large-sized co-
hort studies with a median follow-up period of up to 10 years 
showed that the change from NAFLD to MAFLD criteria might 
identify a greater number of subjects with metabolically compli-
cated FLD and increased risk for CVD.16,23 However, large follow-
up studies are needed to compare the risk of developing impor-
tant extra-hepatic outcomes (e.g., hepatocellular carcinoma or 
other malignancy) of patients with either MAFLD or NAFLD.
Due to the scarcity and controversy of the existing data, it still 
remains unclear whether NAFLD or MAFLD is more feasible in 
clinical practice. More studies comparing the NAFLD and MAFLD 
criteria and stratifying subjects with MAFLD into different risk 
groups are needed to draw firm conclusions.
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